November 01, 2006
2 min read
Save
This article is more than 5 years old. Information may no longer be current.
Progression and treatment of AMD
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Images from patients with age-related macular degeneration treated with pegaptanib sodium (Macugen, Pfizer) illustrate the effects of anti-VEGF therapy.
The case studies below show various types of patients eligible for treatment with pegaptanib.
Results may be specific to these individual patients and may not be observed in all patients with wet AMD.
Small classic lesion |
Source: Suñer I |
Occult lesion with good vision | ||
Source: Verstraeten T |
Large pigment epithelium detachment | |
Baseline 20/50 | |
1 week post 20/40 | |
6 weeks post 20/30 | |
Source: Tolentino M |
Occult lesion with pigment epithelium detachment Source: Tolentino M |